Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2012 by University of Ulm.
Recruitment status was  Active, not recruiting
IMSE, TU Munich (Biometry)
WiSP GmbH, Langenfeld (Monitoring and Data Management)
Central study office of the GCLLSG Cologne
Information provided by (Responsible Party):
Stephan Stilgenbauer, University of Ulm Identifier:
First received: June 28, 2011
Last updated: August 30, 2012
Last verified: August 2012
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2013
  Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)